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1. Introduction 
Timely nutrition assessment and intervention in organ transplant recipients may improve 
outcomes surrounding transplantation. Because nutritional status is a potentially modifiable 
risk factor, the development of strategies designed to optimize nutritional status decreases 
the short-term risks in the post transplant period (Russo et al., 2010). 
Despite many advances in surgical techniques, diagnostic approaches and 
immunosuppressive strategies, survival after heart transplantation is limited by the 
development of cardiac allograft vasculopathy (CAV) which is the most important cause of 
death late after transplantation (Hosenpud et al., 1998; Pethig et al., 1997) and by the adverse 
effects of immunosuppression. 
Primary prevention of CAV in heart transplant (HT) recipients should include strict control 
of cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking and 
obesity), as well as strategies for the prevention of cytomegalovirus (CMV) infection 
(Costanzo et al., 2010). The sum of various risk factors has a negative impact on survival 
(Almenar et al., 2005). In addition, malnutrition increases the risk of infection post 
transplant and may reduce survival (Hasse, 2001). 
It has been referenced that improper dietary habits, low physical activity and the side effects 
of immunosuppressive therapy might explain the weight gain, the altered lipid pattern and 
an increase in insulin resistance after transplant (Evangelista et al., 2005; Flattery et al., 2006; 
Uddén et al., 2003). The metabolic picture after transplantation is also worsened by the 
immunosuppressive drugs (Anker et al., 1997; Kemna et al., 1994). Therefore, the 
development of strategies to reduce post transplant body weight and to improve insulin 
resistance is important (Sénéchal, 2005).  
Immunosuppressive agents, such as prednisone, cyclosporine, mycophenylate mofetil and 
sirolimus, are associated with hyperlipidemia (Bilchick, 2004). The glucocorticoids play a 
major role in the development of post transplant osteoporosis (Epstein & Shane, 1996; 
Epstein et al., 1995; Glendenning et al., 1999; Reid et al., 1988; Rodino & Shane, 1998; Shane, 
2000; Stempfle et al., 1999) and it is known that side effects of glucocorticoids, such as on 
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weight gain and the increase of appetite (Kahn & Flier, 2000; Uddén et al., 2003), may induce 
insulin resistance and diabetes mellitus. 
Osteoporosis is a leading cause of morbidity; the most rapid bone loss occurs during the 
first three months and in the first two years after cardiac transplantation (Hasse, 2001; 
Henderson et al., 1995). 
In addition, statins are usually required in transplant recipients to achieve low LDL 
cholesterol levels. High concentrations of these drugs, particularly in combination with 
cyclosporine, may increase the risk of side effects (Vorlat et al., 2003). 
Recommendations for specific levels of nutrients should be made after the following factors 
are considered: nutritional status, body weight, age, gender, metabolic state, stage and type 
of organ failure, presence of infection, malabsorption or induced losses, goals and comorbid 
conditions (Hasse, 2001). 
The effectiveness of nutritional education should consider a number of psychological 
variables, including social, cultural and ethnicity factors. These variables are present when 
HT recipients return to their usual context. Although not a priority for the survival of the 
person, they are important to the goal of the nutritional action. 
Finally, HT recipients should be provided with a multidisciplinary team, including 
surgeons, cardiologist, nurses, psychologists and dieticians, among many others including 
ancillary services, such as home care nursing, cardiac rehabilitation, psychologic support, 
nutritional planning or patient support groups that can be used as resources in the follow-
up of HT recipients (Costanzo et al., 2010). 
2. Nutritional assessment 
A comprehensive nutritional assessment of transplant recipients should include a variety of 
parameters including physical assessment, history, anthropometric measurements and 
laboratory tests (Hasse, 2001). This method has been used in subjects who were followed for 
four years. During the first year, follow-up visits occurred once a month and they included 
evaluation of anthropometric measurements, body composition, biochemical parameters 
and dietary records; afterwards the body weight, the dietary habits, the physical activity 
level and the biochemical parameters were collected on the phone once a year for three 
years (Guida et al., 2009). 
Various parameters are analyzed in the nutritional status assessment (Sirvent & Garrido, 
2009). 
2.1 Personal interview 
The personal interview is essential to review and investigate certain aspects which may have 
direct bearing on the dietary pattern. Some key items to be considered are discussed in this 
paragraph. 
In relation to food intake, it is necessary to find out the usual pattern (quantity, quality and 
distribution of food intake) in the last days, weeks or months. The assessment is directed at 
whether the intake meets minimum requirements of adequacy and variety. Related to food 
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intake is the appetite, from which we can detect the presence of eating disorders and likely 
food intolerances, and delve into the personal history of diseases that alter appetite. 
From a functional perspective it is necessary to inquire about ability to swallow and on 
digestive function and autonomy which enables food intake. It is also interesting to know 
more about chewing and swallowing patterns, and dental status. Reports on the presence of 
diarrhea, constipation, vomiting and intolerance in general should be included, and the 
degree of independence and autonomy of the person in relation to feeding should be 
checked. 
Finally, we must-take into account all the circumstances which may influence and modify 
eating habits or energy expenditure, like family relationships, group memberships, special 
diets, type and frequency of physical activity, etc. 
2.2 Physical inspection 
Most important items when assessing physical condition are hydration, weight aspect, 
awareness and autonomy. These parameters influence the ability to feed , body temperature, 
colour of skin and mucous and should be considered as merely indicative. This should be 
complemented by biochemical data, anthropometric and dietary history of the subject. 
2.3 Body composition 
Provides information on the percentages of muscle, fat or bone. There are different 
methods: chemical techniques, electrical bioimpedance and anthropometry, among others. 
The anthropometric measurements and bioimpedance are widely used non invasive 
techniques. 
2.3.1 Chemical techniques 
Measurements of chemical techniques include creatinine and 3-methylhistidine. In relation 
to the first technique, the total plasma creatinine concentration is used for determining 
muscle mass, assuming that the creatinine is 98% in muscle tissue and 1 mg of creatinine 
equivalent to 0.88 kg of muscle. This technique only provides data on muscle mass, does not 
evaluate other parameters of body composition and has a number of drawbacks. The 3-
methylhistidine is also used for determining muscle mass. Generally this shows the same 
disadvantages as the previous determination and we must add the complexity of the 
analysis and high cost. 
2.3.2 Bioelectrical impedance analysis 
Body composition can be determined by conventional bioelectrical impedance analysis 
(BIA). The subject should rest in the supine position and a weak current (electric current of 
low voltage high frequency and intensity) is passed between two electrodes placed on one 
hand and another on a foot. The intensity is conducted differently from fat (it acts as 
insulation) than fat-free mass, where water and electrolytes are good conductors. The use of 
this technique has several advantages, including: its relatively low price, ease of equipment 
transportation and its safety. 
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Because BIA equations must consider age, gender, race and body habitus of the patient 
(Dumler, 1997), accuracy of the results also depends on the equations used to determine 
body composition (de Fijter et al., 1997; Pichard et al., 1999). 
Although BIA has become widely available, a single-frequency test may not be valid in 
transplant candidates due to body fluid shifts (Hasse, 2001). 
2.3.3 Anthropometric method 
The anthropometric method is highly recommended for several reasons: it is simple, 
accurate, accessible, comfortable and economical. The reliability depends on the ability of 
anthropometrics and rigor in making measurements. The protocol must be standardized so 
that results can be compared (Sirvent & Garrido, 2009). 
Nutritional anthropometry is based on the study of a number of somatic measures on 
proportions of the human body. The data obtained from anthropometry (weight, height, 
perimeter, diameters, lengths and skin folds) are further processed by application of 
different regression equations and statistical formulas for information on body composition. 
The parameters commonly used are weight, height and body mass index. The weight is an 
easily obtainable and reproducible indicator of body mass. Along with weight, the height 
provides less sensitive information on nutritional deficiencies. However, both parameters 
can be obtained on body mass index, also known as Quetelet index. In particular, BMI is 
defined by body weight in kilograms divided by the square of body height in metres. 
Obesity is characterized by an excess of body fat. Several methods have been introduced to 
quantify obesity. The most common are measurement of body fat by the use of bioelectrical 
impedance techniques and measurements of body density by weighing subjects underwater 
and subsequent calculation of fat mass (Flier, 2001). As it is difficult to ascertain the exact 
amount of body fat, a number of markers have been development to quantify obesity. 
BMI is the most widely used parameter for characterization of abnormalities of body weight 
(Kahn et al., 2006). The recommended classification for BMI adopted by the Expert Panel on 
the Identification, Evaluation and Treatment of Overweight and Obesity in Adults, and 
endorsed by the National Institute of Health and the WHO is: BMI<18.5 (underweight), 18.5 
to 24.99 (normal weight), 25 to 29.99 (overweight), 30 to 34.99 (obesity class I), 35 t0 39.99 
(obesity class II) and ≥ 40 (obesity class III) (National Heart, Lung and Blood Institute, 1998). 
BMI at the time of transplant is an important predictor of post transplant outcomes, 
including survival, perioperative morbidity, post transplant cardiovascular comorbities, 
long-term complications of transplantation and survival on the waiting list. HT recipients 
across a broad range of BMI (including normal, overweight and obesity I subgroups) 
achieved good long-term post transplant outcomes. However, recipients at the extremes 
(e.g. underweight and obesity II/III) have significantly higher morbidity and mortality 
compared with other groups. This diminished survival in the underweight (BMI<18,5) 
group resulted from excess morbidity in the first year post transplantation. However, with 
correction of their heart failure and subsequent reversal of their cachectis state, their risk of 
death along with the mean BMI, normalized after the initial post transplant period. Obesity 
II/III (BMI>35) was also associated with diminished survival, however, this appears to 
result from higher morbidity and mortality over the long-term (Russo et al., 2010). 
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In cardiac surgery patients, a low BMI increased the relative hazard for death and low S-
album increased the risk for infection. Rapp-Kesek et al. suggest that these parameters 
provide useful information in the preoperative evaluation (Rapp-Kesek et al., 2004). 
On the other hand, skin folds and body parameters are widely used (Sirvent & Garrido, 
2009). 
In this sense, the most common measures used are Triceps skin fold (PT), Circular 
circumference of the arm (CB) and Arm muscle circumference (AMC). PT allows us to assess 
fat mass. It is expressed in mm, and its measurement is made with a calliper at the midpoint 
between the acromion and the olecranon. On the other hand, CB provides information about 
the total mass and is measured with a tape measure midway between the acromion and the 
olecranon and expressed in cm. Last, AMC is used to assess muscle mass. It is expressed in 
cm and is calculated: CMB (cm) = CB (cm) -0.314 x PT (mm). 
2.3.4 Biochemical parameters 
Biochemical parameters make possible obtaining more information on nutritional status. 
They are (among others): 
 Albumin is one of the most used. This protein has a long half life (18-20 days), so their 
determination is a few sensitive markers in recent nutritional disorders. Instead it may 
be useful to assess long and serious situations of malnutrition. The normal 
concentration for adults is ≥ 3.5 g/dl. Hypoalbuminemia presents low risk values 
between 2.8 and 3.4 g/dl and hypoalbuminemia high-risk values are below 2.8 g/dl. 
 Transferring is also widely used. It has a shorter half life between 8 and 10 days. Its 
main function is iron transport functions. It is more sensitive than albumin to 
nutritional changes and responds more quickly to changes in protein status. Normal 
levels are between 150 and 200 mg/dl. It considers moderate deficiency between 100 
and 150 mg/dl and severe deficiency below 100 mg/dl. 
 Prealbumin is a transport protein with a half life of 2 days. It decreases rapidly when 
calorific intake or protein is low and responds very quickly to nutritional rehabilitation. 
Normal values are between 10 and 40 mg/dl. 
 Retinol transport protein has a very short half life of approximately 12 hours. Its values 
are normal at 7.6 mg/dl. Sensitivity to protein-energy deprivation is high, but lacks (as 
prealbumin) diagnostic specificity due to the impact of other processes on its levels. 
 Fibronectin. Studies have shown low levels in situations of fasting and acute protein-
energy malnutrition. Its normalization with nutritional rehabilitation is rapid. Normal 
values are around 169 mg/ml. 
 Nitrogen balance provides information on the protein reserve. We reserve its use to 
situations where we want to have guidance on protein balance in a given time. 
 Lymphocyte count, based on an adequate supply of energy and protein is essential for 
maintaining normal immune function. The drawbacks are its low specificity because it 
can be altered by multiple factors and the other limitation is that only the lymphocyte 
count is altered in situations when malnutrition is established. 
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Finally, we mention the existence of other parameters used in specific situations, such as 
vitamin A, vitamin E and so on. Measurement and interpretation of waist circumference and 
fasting triglycerides could be used among heart transplant patients for early identification of 
men characterized by the presence of elevated fasting insulin and apolipoprotein B 
concentration, and small LDL particles. The presence of the atherogenic metabolic triad 
identifies patients at high risk of coronary artery disease, even in the heart transplant 
population (Sénéchal et al., 2005). 
3. Nutritional intervention 
Nutrition is extremely important in the care of patients undergoing transplantation (Helton, 
2001). Following an appropriate and strict dietary regimen after the HT reduces risk factors 
and should be considered seriously (Guida et al., 2009). 
During the acute post transplant phase, adequate nutrition is required to help prevent 
infection, promote wound healing, support metabolic demands, replenish lost stores and 
perhaps mediate the immune response (Hasse, 2001). 
The HT recipient must have two main dietary goals: a healthy and balanced diet (to provide 
all the necessary nutrients and avoid new heart attacks) and to maintain strict hygiene 
measures to reduce germs in food (Casado, 2005). 
With regard to the rules of food hygiene, there are a number of recommendations among 
which are: do not take raw food during the first six months post transplant (considered the 
highest risk); casseroles prepared at home, if not eaten immediately after cooking, should be 
kept in the fridge covered and consumed within 24 hours; do not add anything raw to the 
preparation; it is preferable to keep sauces separate (Casado, 2005). 
A diet of cardiovascular protection should include the following considerations about 
certain parameters: 
3.1 Overweight 
Some investigators have described excessive weight gain following cardiac transplant 
(Baker et al., 1992; Johnson et al., 2002; Keteyian et al., 1992; Lake et al., 1993). On average 
these patients gain approximately 10 kg within the first year after the procedure. This 
weight gain increases the risk of secondary diseases (i.e. hypertension, diabetes and 
dislipemias) (Williams, 2006). 
Patients who were underweight or obese at one year post transplant were at greater risk of 
rejection over time than patients who were of normal weight or overweight. Post transplant 
cachexia and obesity are risk factors for poor clinical outcomes after heart transplantation. 
Grady et al. found that risk factors for increased body weight at one year after heart 
transplantation included both demographic factors (BMI at the time of transplant, younger 
age, black race) and clinical variables (etiology of heart disease, immunosuppression) 
(Grady, 2005). 
After HT, regular weight-bearing and muscle-strengthening exercise should be encouraged 
to reduce the risk of falls and fractures, and to increase bone density. Lifestyle modifications, 
including weight loss, low-sodium diet and exercise are appropriate adjuncts to facilitate 
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control of blood pressure in HT recipients (Costanzo et al., 2010). The clinicians may assist 
patients to make changes in their post transplant lifestyle to return to a normal body weight. 
Guida et al. showed the efficacy of dietary intervention to obtain an early and late weight 
and metabolic control after HT. All subjects received a dietary plan that was elaborated to fit 
an energy intake ≥ 25 Kcal/Kg/Ideal Body Weight/day, with 55% of carbohydrates, 15% of 
protein and 30% of total fat (fatty acids <10% of calories and dietary cholesterol <300 mg/d 
according the American Heart Association step one diet guidelines) (The Expert Panel, 
1988). The patients were prescribed low-salt food in order not to exceed sodium content of 
1.5 g/d and they were asked to limit the amount of additional salt to 3 g/d. In this diet plan 
all subjects were encouraged to increase their physical activity level up to 30 min/d three 
times a week and they were strongly recommended to modify some of their habits (Guida et 
al., 2009). 
To reach this goal it is indispensable to carry out an early and comprehensive programme 
providing a plan of nutritional interventions, education and lifestyle counselling. They 
demonstrated that dietary compliance is helpful to get a good early and late control in 
weight and metabolic parameters, both in subjects enrolled during the first year from the 
transplant and after the first year from the transplant, even if high doses of 
immunosuppressive therapy are used. The beneficial effects of this intervention are still 
maintained after a 48-month follow-up period (Guida et al., 2009). 
Incorporation of a weight loss plan, including diet, exercise and psychologic interventions 
into the discharge process with subsequent outpatient follow-up is recommended. The 
psychological interventions are often incorporated into a comprehensive weight loss 
programme (Grady, 2005). 
The scientific literature shows different mood disorders in both the situation prior to 
transplantation and thereafter; the most common that have been tested are the anxiety 
disorders, depression and post traumatic stress disorder (Perez San Gregorio et al., 2005; 
Spaderna et al., 2007) and they have been found to adversely affect the ability to accept the 
new organ. 
This negative emotion affects different areas of the daily life of transplant patients, including 
nutritional status, either with a decreased or increased appetite, and consequently a loss or 
weight gain, which is contraindicated in patients transplanted. 
Although a variety of weight loss programmes exist, it may be beneficial to consider weight 
loss plans that are individualized and tailored to incorporate the patient’s clinical status, 
age, cultural background, dietary preferences, exercise history, socio-economic and 
behavioural factors etc. Many patients also have established patterns of cooking and eating 
based on cultural background (Grady, 2005). 
Moreover, the goal of a dietary intervention should be to optimize the nutritional status and to 
preserve the long-term renal function by avoiding unnecessary protein loads (Al et al., 2005). 
With respect to lipid metabolism, the increase in body weight is correlated with the increase 
in serum lipid level during the first year after the transplant (Grady et al., 1991; Keogh et al., 
1988), whereas a decrease in body weight or energy intake is effective to reduce blood 
cholesterol level (Kannel et al., 1979; Nichols et al., 1976; Kromhout, 1983). 
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3.2 Malnutrition 
Harrison et al. defined malnutrition as midarm muscle circumference and triceps skin fold 
measurement <25th percentile (Harrison et al., 1997). The malnutrition diagnosed by 
subjective and objective nutrition assessment parameters is common in solid organ 
transplant recipients and leads to increased morbidity and mortality (Helton, 2001). 
Because malnutrition is a marker of worsening heart failure (Anker et al., 1997) and is a 
known risk factor for poor outcomes after surgery (Buzby et al., 1980; Rady et al., 1997) low 
BMI may in fact be a stronger predictor of poor outcomes than obesity. The BMI is 
potentially modifiable through medical management and/or lifestyle changes (Russo et al., 
2010). 
Patients with chronic heart failure are often malnourished as a result of maldigestion, 
malabsorption and poor nutrient assimilation. This is compounded by the fact that many of 
these patients have a prolonged catabolic state characterized by increased energy 
expenditure coupled with anorexia and inadequate dietary intake. 
Malnourished patients undergoing transplantation have increased morbidity and mortality, 
and increased overall hospital charges. Patients surviving transplantation have altered lipid 
and fat metabolism, and problems with obesity and accelerated atherosclerosis leading to 
cardiovascular death (Helton, 2001). 
3.3 Dyslipidemia 
Dyslipidemia is common after cardiac transplantation. Multiple factors in transplant 
recipients promote dyslipemia: inappropriate diet in combination with reduced physical 
activity, immunosuppression with cyclosporine and steroids, anti-hypertensive agents and 
concomitant conditions, such as diabetes, obesity, age and male gender. Total and low-
density lipoprotein (LDL) cholesterol are prominent risk factors for major progression of 
CAV disease (Pethig et al., 2000). 
To accommodate the lipid profile the following is recommended: a cholesterol intake below 
300 mg per day, to limit total dietary fat to less than 30% of total calories, to limit saturated 
fats to less than 10% of total calories, to increase mono- and polyunsaturated fat (the latter 
about 7% of total calories) (Casado, 2005). 
In recent years the benefit of certain food components has been referenced. Phytosterol, 
plant stanol and sterol esters, reduce serum cholesterol by inhibition of cholesterol 
absorption. Substitution of part of the daily fat intake with stanol ester margarine has been 
shown to reduce serum cholesterol by 10.2% and LDL cholesterol by 14% after one year 
(Miettinen et al., 1995). 
Margarine containing stanol/sterol esters is a safe, simple and efficient way to reduce total 
LDL cholesterol in patients after cardiac transplantation. The tolerance of the margarine 
containing stanol or sterol esters is good. It is possible to reduce the dose of statins while 
maintaining LDL cholesterol at <115 mg/dl (Vorlat et al., 2003). The concomitant use of 
statins and stanol esters has shown additional lipid-lowering effects (Blair et al., 2000). 
Phytosterol therapy produces an average 10-11% reduction in LDL cholesterol 
concentration, but it is unknown whether this effect persists beyond two years. Phytosterol 
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products are well tolerated and have few drug interactions, but their long-term safety has 
not been established. Current evidence is sufficient to recommend phytosterol for lowering 
LDL cholesterol in adults (Malinowski & Gehret, 2010). 
On the other hand, ω-3 fatty acids have been studied in cardiac transplant recipients treated 
with cyclosporine and have been found to have beneficial effects on hypertension 
(Andreassen et al., 1997; Holm et al., 2001) and coronary endothelial function (Fleischhauer 
et al., 1993). They may also be added to statin therapy in cardiac transplant recipients with 
persistent hypertriglyceridemia. An ω-3 fish oil preparation consisting of 80% ω-3 
polyunsaturated fatty acids (44% eicosapentaenoic acid and 36% dehydroacetic acid) when 
used with simvastatin has been shown to reduce triglyceride levels by an additional 20-30% 
(Durrington et al., 2001). When triglyceride levels are >200 mg/dl after LDL-lowering 
therapy, a trial of an ω-3 concentrate or fish oil (which usually contains approximately 35% 
ω-3 polyunsaturated fatty acids) is reasonable because of the potential benefits and 
favourable safety profile (Bilchick et al., 2004). 
3.4 Beneficial effects of certain nutrients 
There are investigations that demonstrate that single nutrients, such as arginine, ω-3 fatty 
acids and pyruvate, and the fasted and post absorptive state can dramatically alter the short 
and long-term function of transplanted organs (Helton, 2001). 
Nutrition also may be used to help treat symptoms of end-stage organ failure. For example, 
an increased intake of calories and protein should help deter fat and muscle loss. Fluid 
retention can be treated with dietary sodium restriction. Branched-chain amino acid-
enhanced formulas may be helpful for patients with intractable hepatic encephalopathy. 
Adequate intake of iron, folic acid and B vitamins can prevent or treat anaemia. Medium-
chain triglyceride supplementation may be useful when steatorrhea and long-chain fat 
malabsorption are present (Hasse, 2001). 
3.4.1 Calcium and vitamin D 
Calcium and vitamin D are necessary when patients have osteoporosis or renal 
osteodystrophy (Hasse, 2001). Magnesium depletion (hypomagnesemia has been 
documented in cardiac transplant recipients) which may be the results of diuretic therapy, 
has been implicated as a risk factor for osteoporosis. 
After transplantation, there is further acceleration in bone loss. Factors associated with 
congestive heart failure that may contribute to bone loss include cardiac cachexia, reduced 
exercise or immobilisation, smoking, alcohol abuse, low calcium intake, heparine 
administration and loop diuretics (Pisani & Mullen, 2002). Vitamin D deficiency is 
significantly more common in the patients with more severe heart failure (Rodino & Shane, 
1998). 
Optimal treatment of osteoporosis requires adequate calcium and vitamin D intake. The 
Institute of Medicine recommends calcium intakes of 1000 to 1500 mg/d (depending on age 
and menopausal status) for adults (NIH, 2001) and vitamin D (400-1000 IU, or as necessary 
to maintain serum 25-hydroxyvitamin D levels above 30 mg/ml= 75 nmol/L) (Costanzo et 
al., 2010). Of note, bone loss occurs despite supplementation with vitamin D and calcium 
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(Shane et al., 1997). The use of calcium and vitamin D supplements, although recommended, 
is inadequate for the prevention of bone loss and complications such as vertebral fractures 
(Pisani & Mullen, 2002). 
3.4.2 Folic acid 
The aminoacid homocysteine has recently been identified as a risk factor for native coronary 
artery disease (Welch et al., 1997) and even mild to moderate hyperhomocysteinemia is 
associated with premature vascular disease (Kark et al., 1999). Growing evidence suggests 
that elevated total plasma homocysteine levels (tHCY) are associated with CAV following 
heart transplantation (Kutschka et al., 2001). 
The homeostasis of homocysteine is altered in solid organ transplant recipients and may be 
partially caused by cyclosporine. The cyclosporine may be associated with secondary 
hyperhomocysteinemia by inducing renal insufficiency. 
Homocysteine is formed by the transmethylation of methionine. Its catabolim is either 
through a folate-cobalamin dependent remethylation pathway catalyzed by methionine 
synthase, or by transsulfuration by cystationine-synthasa, a vitamin B6-dependent enzyme 
(Chan, 2001). 
Beside parameters like age (Kark et al., 1999), sex (Selhub et al., 1999), genetic determination 
(Deloughery et al., 1996) and renal function (Moustapha et al., 1998) are influenced by 
dietary intake of vitamins B6, B12 and folic acid (Selhub et al., 1999; Verhoef et al., 1996). 
Hyperhomocysteinemia as well as deficiencies in folate and vitamin B6 are common in HT 
recipients, especially in older individuals and patients with renal insufficiency (Kutschka et 
al., 2001). 
Folic acid supplementation (5 mg per day) provides a simple and effective measure to lower 
elevated tHCY concentrations without side effects (Kutschka et al., 2001, Chan, 2001). 
3.4.3 L-Arginine 
Endothelial dysfunction is associated with the decreased exercise capacity observed in HT 
recipients. L-Arginine supplementation (LAS) increases nitric oxide (NO) and decreases 
endothelin-1 plasma concentrations, thereby improving endothelial function and exercise 
capacity in heart failure or HT patients (Doutreleau et al., 2004; Rector et al., 1996). 
The NO/endothelin ratio significantly increases after chronic LAS, suggesting that the 
beneficial effects of L-Arginine (amino acid precursor of NO production) on the exercise 
capacity of patients after an HT might, at least partly, be related to an improvement in 
skeletal muscle vasodilatation and oxygen delivery, and extraction during exercise as 
suggested by the significant increase in the oxygen pulse after LAS. This pilot study 
provides support that oral LAS may be a useful adjuvant therapy to improve the quality of 
life and exercise tolerance in HT recipients (Doutreleau et al., 2010). The L-Arginine-NO 
pathway has been recognized to play critical roles during infection, inflammation, organ 
injury and transplant rejection (Helton, 2001). 
These dietary interventions, when used in combination with other therapies, may improve 
the quality of life of patients (Hasse, 2001). 
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3.5 Side effects of cyclosporine 
Cyclosporine has significant effects on the metabolism and disposition of several 
biomolecules. Hyperglycemia, hypercholesterolemia and electrolyte disturbances are a few 
of its common side effects. Hyperkalemia (cyclosporine has a direct effect on the renin-
angiotensin-aldosterone system which further worsens potassium homeostasis [Bantle et al., 
1985]) and hypomagnesemia are the two most frequently observed electrolyte disorders 
caused by this calcineurin inhibitor. 
Patients taking cyclosporine should be educated on their dietary potassium intake (the 
hypertension is another common side effect of cyclosporine). Most patients will 
subsequently require oral supplementation of magnesium to maintain a normo-magnesic 
state and the chronic hypomagnesemia may affect parathyroid function and rennin activity 
(Ichihara et al., 1993; Mori et al., 1992; Navarro et al., 1999). The altered parathyroid 
hormone activity can have a secondary effect on calcium and vitamin D disposition, and 
may indirectly contribute to post transplant osteoporosis (Grenet et al., 2000; Thiébaud et al., 
1996). 
3.6 Mediterranean diet 
It has been suggested that the healthy effects of the Mediterranean diet observed in 
epidemiologic studies are exerted partly through plausible mechanisms: improved lipid 
profiles (Bemelmans et al., 2002; Zambón et al., 2000) and reductions in blood pressure 
(Perona et al., 2004) , insulin resistance and systemic markers of inflammation (Chrysohoou 
et al., 2004; Esposito et al., 2004). These beneficial effects on surrogate markers of 
cardiovascular risk add biological plausibility to the epidemiologic evidence that supports 
the suggested protective effects of the Mediterranean diet (Estruch et al., 2006). Moreover, 
the Mediterranean diet could protect against the development of coronary heart disease, not 
only because of its beneficial role regarding cardiovascular risk factors, but also due to a 
possible effect on body weight and obesity (Kastorini et al., 2010). 
4. Drug-nutrient interaction 
HT recipients are polymedicated patients; they use multiple medications to manage graft 
rejection, opportunistic infections and other associated complications. This patient 
population has a very high risk of drug-nutrient interactions (Chan, 2006). In some cases, the 
interactions are not identified until serious adverse events have occurred. 
The consequences of unrecognized and unmanaged drug-nutrient interactions in the 
transplant recipient can be very serious and these adverse outcomes represent important 
contributing factors to post transplant morbidity and mortality (Chan, 2001). 
Drug-nutrient interactions can significantly affect the availability and potency of 
immunosuppressive therapy. Alterations in food intake, inadequate digestion and these 
interactions can lead to changes in the pharmacokinetics of immunosuppressive drugs 
leading to either toxicity or organ rejection as a result of inadequate blood drug levels 
(Helton, 2001). 
Drugs have the potential to interact with nutrients, which could lead to the reduced 
therapeutic efficacy of the drug, nutritional risk or increased adverse effects of the drug. 
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Food-drug interactions are defined as alterations of pharmacokinetics or pharmacodynamics 
of a drug or nutritional element, or a compromise in nutritional status as a result of the 
addition of a drug. Nutrient-drug interactions can result in two clinical effects: either a 
decreased bioavailability of a drug, which predisposes to treatment failure, or an increased 
bioavailability, which increases the risk of adverse events and may even precipitate 
toxicities (Genser, 2008). 
On the other hand, medications can lead to altered food choices. Many drugs are reported to 
directly affect the sense of taste and smell, and some drugs themselves have an unpleasant 
taste that might interfere with food intake (Brownie, 2006). 
The evidence that water-soluble vitamin E interacts with orally administered cyclosporine is 
quite convincing. This interaction has only been observed with water-soluble formulation of 
vitamin E. Further investigations using different dosage forms of vitamin E are necessary. 
Grapefruit juice-drug interactions represent some of the most significant examples of drug-
nutrient interactions. When a single dose of cyclosporine was taken with 200 mL of 
grapefruit juice, its absorption was increased. The reported increase in bioavailability of 
cyclosporine ranged from 17% to 63% (Chan, 2001). 
Other drugs with increased absorption when taken with grapefruit juice are atorvastatin 
and sertralin (Chan, 2006). 
5. Conclusion 
It is necessary to make more efforts in studying the metabolic syndrome in transplant 
patients and how this syndrome can affect the transplanted graft. 
There are still many doubts about the interactions between different drugs used, nutrients 
and other substances in the diet. Moreover, further studies are needed to provide 
information on the potential benefit that some types of diet (such as the Mediterranean), 
antioxidants or other molecules present in the diet can contribute to the benefit of patients. 
Moreover, not only is it important to know that various substances can be beneficial, it is 
also important to know the amount we can use. 
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